PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'Smart' drug aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus or rheumatoid arthritis that haven't improved with standard treatments. CC312 works like a bridge, guiding the body's immune cells to attack and destroy fault…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
New IVIG trial hopes to boost platelets in bleeding disorder
Disease control Recruiting nowThis study tests a medicine called human immunoglobulin (IVIG) given through a vein for 5 days in a row. It aims to raise platelet counts and reduce bleeding in adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. About 36 par…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Grand Shuyang Life Sciences (Chengdu) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy aims to boost platelets in Hard-to-Treat ITP patients
Disease control Recruiting nowThis study tests whether adding rituximab to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. About 224 participants will receive either the combination or eltrombopag alone, a…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy aims to tame rare bleeding disorder
Disease control Recruiting nowThis study tests whether adding the drug ianalumab to a standard platelet-boosting therapy is tolerable for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have tried at least one…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug aims to boost platelet counts in chronic ITP patients
Disease control Recruiting nowThis study tests an investigational IV drug called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. About 69 participants will receive either the drug or a placebo for up to 24 weeks…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug combo aims to boost platelet counts in ITP patients
Disease control Recruiting nowThis study tests whether adding orelabrutinib to high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. About 86 participants will receive either …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Shandong University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New shot aims to boost platelets in ITP patients
Disease control Recruiting nowThis study tests a new medicine called STSA-1301, given as a shot under the skin, for people with immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The trial involves 56 healthy volunteers and ITP patients to check safe…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New shot aims to boost platelets in rare bleeding disorder
Disease control Recruiting nowThis early study tests a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive one injection and are monitored for safety and platelet count changes. The go…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC